Discussing the harms and benefits of aspirin
colorectal cancer
REGRESSION, COLORECTAL CANCER
Most GPs felt comfortable discussing aspirin harms and benefits with the hypothetical patient (361/672, 53.7% quite comfortable; 150/672, 22.3% very comfortable), whereas 24.0% were uncomfortable with these discussions (130/672, 19.3% quite uncomfortable; 31/672, 4.6% very uncomfortable). GPs’ comfort discussing aspirin harms and benefits was comparable across the three components (NICE guidance; CAPP2 results; risk and benefit information; Supplementary Table S3). There was no statistically significant main effects or interactions of the components on comfort discussing aspirin (Supplementary Table S3).In the multivariable logistic regression model, GPs who reported awareness of aspirin for colorectal cancer prevention in people with LS were more comfortable discussing benefits and harms than those who were unaware before the survey (OR = 1.68, 95% CI = 1.06 to 2.72, 